T1	Participants 40 118	cell-derived microparticles during cardiac surgery with cardiopulmonary bypass
T2	Participants 292 361	patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)
T3	Participants 504 515	13 patients
